An Expanded Access Program (EAP), sometimes called 'compassionate use,' is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

At this time, Vasa does not have an EAP available for VS-041 for the treatment of HFpEF patients but will provide any updates here/on the company website once available. If you have any questions about our expanded access policy, please contact us at clinical@vasatherapeutics.com‍